Volume 22, Issue 3 (5-2018)                   IBJ 2018, 22(3): 140-141 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Roohvand F. Streptokinase for Treatment of Thrombotic Disorders: The End? Or the End of the Beginning?. IBJ 2018; 22 (3) :140-141
URL: http://ibj.pasteur.ac.ir/article-1-2256-en.html
Thrombotic disorders, such as myocardial infarction, ischemic stroke, peripheral arterial disease, deep venous thrombosis, pulmonary embolism, or other embolic diseases that are responsible for worldwide mortality and morbidity, are manifestations of the formed thrombi by blood clots during a pathologic blood coagulation process. Once thrombi are formed, the only way to resolve the blood clot is treatment with specific thrombolytic agents, so called plasminogen activators (PAs), such as tissue-PAs (tPAs), urokinase, and streptokinase (SK). PAs convert the endogenous human plasminogen (HPG: the inactive proenzyme) to plasmin (HPM: the active enzyme), which cleaves the fibrin network of the blood clot, a process known as fibrinolysis (Fig. 1)...
Type of Study: Study Break | Subject: Related Fields

Add your comments about this article : Your username or Email:

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Iranian Biomedical Journal

Designed & Developed by : Yektaweb